[1] Cherney DZ.Advances in the treatment of diabetic nephropathy[J].Nephrol News Issues,2013,7(5):18,33.[2] Appel G.Detecting and controlling diabetic nephropathy:what do we know[J]. Cleve Clin J Med,2013,80(4):209-217.[3] Singh AK, Singh J. Evaluation of anti-diabetic potential of leaves and stem of Flacourtia jangomas in streptozotocin-induced diabetic rats[J]. Indian J Pharmacol,2010, 42(5):301-305.[4] Chandak PG, Gaikwad AB, Tikoo K. Gallotannin ameliorates the development of streptozotocin-induced diabetic nephropathy by preventing the activation of PARP[J]. Phytother Res, 2009, 23(1):72-77.[5] Brownlee M. The pathobiology of diabetic complications:a unifying mechanism[J]. Diabetes, 2005, 54(6):1615-1625.[6] Smith MA, Hampton OA, Reynolds CP, et al. Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program:PALB2 mutation predicts exceptional in vivo response to BMN 673[J]. Pediatr Blood Cancer, 2015, 62(1):91-98.[7] Jang NY, Kim DH, Cho BJ, et al. Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer[J]. BMC Cancer, 2015, 15:89.[8] Yao H, Ji M, Zhu Z, et al. Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose) polymerase-1 inhibitors[J]. Bioorg Med Chem, 2015, 23(4):681-693.[9] Faraoni I, Compagnone M, Lavorgna S, et al. BRCA1, PARP1 and γH2AX in acute myeloid leukemia:Role as biomarkers of response to the PARP inhibitor olaparib[J]. Biochim Biophys Acta, 2015, 1852(3):462-472.[10] Lupachyk S, Shevalye H, Maksimchyk Y, et al. PARP inhibition alleviates diabetes-induced systemic oxidative stress and neural tissue 4-hydroxynonenal adduct accumulation:Correlation with peripheral nerve function[J]. Free Radic Biol Med, 2011, 50(10):1400-1409.[11] Gunderson CC, Moore KN. Olaparib:an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer[J]. Fut Oncol, 2015, 11(5):747-757.[12] Li Y, Fan L, Sun Y, et al. Paris saponin Ⅶ from trillium tschonoskii reverses multidrug resistance of adriamycin-resistant MCF-7/ADR cells via P-glycoprotein inhibition and apoptosis augmentation[J]. J Ethnopharmacol, 2014, 154(3):728-734.[13] Durmus S, Sparidans RW, van Esch A, et al. Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) restrict oral availability and brain accumulation of the PARP inhibitor rucaparib (AG-014699)[J]. Pharm Res, 2015, 32(1):37-46.[14] Henneman L, van Miltenburg MH, Michalak EM, et al. Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer[J]. PNAS, 2015, 112(27):8409-8414.[15] Jaspers JE, Sol W, Kersbergen A, et al. BRCA2-deficient sarcomatoid mammary tumors exhibit multidrug resistance[J]. Cancer Res, 2015, 75(4):732-741.[16] Tikoo K, Tamta A, Ali IY, et al. Tannic acid prevents azidothymidine (AZT) induced hepatotoxicity and genotoxicity along with change in expression of PARG and histone H3 acetylation[J]. Toxicol Lett, 2008, 177(2):90-96.[17] Shevalye H, Stavniichuk R, Xu W, et al. Poly(ADP-ribose) polymerase (PARP) inhibition counteracts multiple manifestations of kidney disease in long-term streptozotocin-diabetic rat model[J]. Biochem Pharmacol, 2010, 79(7):1007-1014.[18] Shevalye H, Maksimchyk Y, Watcho P, et al. Poly(ADP-ribose) polymerase-1(PARP-1) gene deficiency alleviates diabetic kidney disease[J]. Biochim Biophys Acta,2010,1802(11):1020-1027. |